Amondys 45 access in the United Arab Emirates: the EDE named-patient pathway

Last reviewed 2026-05-12 by the Reserve Meds clinical and regulatory team. This page combines the UAE country research module with the Amondys 45 drug module to describe the path families actually walk.

Quick orientation

Amondys 45 (casimersen) is a phosphorodiamidate morpholino oligomer (PMO) developed by Sarepta Therapeutics. The US Food and Drug Administration approved Amondys 45 in February 2021 under the accelerated approval pathway for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 45 skipping, an estimated 8 percent of the DMD population. The drug is given by intravenous infusion once weekly at a dose of 30 mg/kg. Treatment is chronic and lifelong. Reserved for you.

Why UAE patients need Amondys 45 via a named-patient pathway

Duchenne muscular dystrophy carries a meaningful prevalence across the UAE pediatric neurology population, with regional consanguinity rates supporting the case for early genetic confirmation. Sarepta's exon-skipping family (Exondys 51 for exon 51, Vyondys 53 for exon 53, Amondys 45 for exon 45) is not consistently held in UAE federal stock, and the drug-mutation match is patient-specific by design. A child with a DMD deletion amenable to exon 45 skipping does not receive Exondys 51 or Vyondys 53; the molecule has to match the mutation. The UAE practical access pattern is therefore named-patient import from the US once the genetic confirmation is in hand.

Two additional access considerations apply. First, Sarepta's exon-skipping family carries accelerated approval status in the US, with confirmatory trials ongoing. Second, the FDA-approved label requires baseline kidney function assessment before treatment, with quarterly monitoring during therapy because PMOs accumulate in renal tubular cells. Both points are documented in the EDE clinical justification and are part of why the treating neuromuscular specialist's role is central.

The EDE / MoHAP named-patient pathway applied to Amondys 45

The federal pathway for a UAE-licensed physician to obtain a medicine that is not registered or not stocked locally is the unregistered-medicine import permit, administered through the Emirates Drug Establishment (EDE) at ede.gov.ae. The EDE took over 44 core services from MoHAP under Federal Decree-Law No. 38 of 2024. The framework allows hospitals and licensed pharmaceutical establishments to import a specific medicine for a specific patient when the medicine is approved by a recognised reference authority such as the US FDA and a locally registered alternative is not suitable.

For Amondys 45, the clinical justification packet has three pillars. First, genetic confirmation. The patient's DMD gene mutation must be confirmed amenable to exon 45 skipping by a laboratory report, typically from a CAP-accredited or comparable laboratory, with the deletion or duplication boundaries explicit so the exon-skip rationale is documented. Second, baseline neuromuscular assessment. The treating pediatric neurologist or neuromuscular specialist documents ambulation status (typical patient is ambulatory or in transition), corticosteroid regimen (most DMD patients are on a deflazacort or prednisone backbone), cardiac assessment, and pulmonary function. Third, baseline renal function. Serum cystatin C and urine dipstick for protein are checked before therapy and quarterly during therapy.

A complete EDE application for an Amondys 45 case typically includes the neuromuscular specialist's clinical justification letter, the laboratory report confirming the exon-45-amenable mutation, the treating physician's MoHAP, DHA, DoH, or Sharjah Health Authority licence verification, an anonymised patient identifier, full product details for Amondys 45 (50 mg/mL or 100 mg/mL single-dose vials), the destination dispensing infusion facility name with licence number and pharmacy in charge, the cold-chain handling plan, and the patient/family informed consent. Approval timelines for routine cases are 5 to 15 business days. The first-of-kind submissions for exon-skipping antisense oligonucleotides typically fall in the 4-to-6-week complex band the first time an institution submits.

Where Amondys 45 gets dispensed in the UAE

Amondys 45 is administered by once-weekly intravenous infusion over 35 to 60 minutes. The dispensing site is the infusion suite at a pediatric neurology centre attached to a licensed pharmaceutical establishment. The most natural candidates in the UAE are the pediatric neurology services at Sheikh Khalifa Medical City, Cleveland Clinic Abu Dhabi, Al Jalila Children's Specialty Hospital in Dubai, and American Hospital Dubai. Tawam Hospital in Al Ain handles pediatric neurology cases nationally and has an attached infusion capability. The drug is supplied as single-dose vials and must be stored refrigerated at 2 to 8 degrees Celsius until the infusion is prepared.

Once-weekly infusions over multiple years are an operational commitment. Families typically choose a dispensing facility on the basis of travel distance from home and continuity of the treating neuromuscular team. Reserve Meds does not select the infusion site on the family's behalf. We coordinate the regulatory documentation and the logistics; the treating neurologist and the family pick the centre.

Real cost picture for Amondys 45 in the UAE

The US wholesale acquisition cost for Amondys 45 is approximately USD 750,000 per year for an average-weight pediatric patient at the 30 mg/kg weekly dose, scaling with body weight as the child grows. In AED at the 3.67 peg, that is approximately AED 2.75 million annually. The figure is the drug acquisition cost only. It does not include the once-weekly infusion suite fees, the quarterly renal monitoring, the cardiac and pulmonary surveillance the DMD multidisciplinary team performs, or any concurrent gene therapy or corticosteroid backbone.

All-in delivered cost stacks the drug acquisition cost, refrigerated international logistics (approximately USD 1,000 to 2,000 per shipment), the EDE handling and customs fees (USD 400 to 800 per case typically), the dispensing facility's infusion fees, and the Reserve Meds concierge coordination fee. We quote each case after the documentation review. Insurance in the UAE handles rare-disease pediatric biologics case by case. Thiqa, administered by Daman for UAE nationals in Abu Dhabi, has the broadest specialty coverage. Daman, GIG Gulf, Sukoon, ADNIC, and Orient each pre-authorise rare-disease cases. We supply the documentation set that lets your insurer assess the case. We do not promise coverage from any insurer.

Typical timeline for Amondys 45 in the UAE

The EDE permit is the regulatory gating step. For a first-of-kind exon-skipping antisense oligonucleotide submission, the institution should plan for the 4-to-6-week complex window the first time, dropping to the 5-to-15 business-day routine band once the institution has a precedent on file. Refrigerated logistics from the US to the UAE add approximately 5 to 10 business days. Customs clearance is typically 1 to 3 business days when the documentation is clean. The first weekly infusion follows immediately on a baseline-checked patient. A family who completes the documentation in week one typically receives the first infusion in week six to week ten for a first-of-kind case and week three to week five for subsequent shipments.

What your physician needs to provide

The clinical justification letter for an Amondys 45 EDE submission is anchored on the genetic confirmation. The treating pediatric neurologist or neuromuscular specialist's letter typically addresses the diagnosis (genetically confirmed DMD), the specific dystrophin gene mutation with the laboratory report attached, the documented amenability to exon 45 skipping, the patient's ambulatory status, the corticosteroid regimen, the cardiac and pulmonary baseline, the baseline renal function (serum cystatin C, urine protein), and the patient's weight-based dose calculation at 30 mg/kg weekly. The letter references the Sarepta US label and the accelerated approval status.

Three documents sit alongside the letter. The genetic laboratory report with the deletion or duplication boundaries explicit. The DMD multidisciplinary care plan documenting cardiac and pulmonary surveillance. The family informed consent reflecting the lifelong weekly infusion commitment and the accelerated-approval context. The treating physician's licence must be in active standing in the emirate of the dispensing facility (MoHAP for the Northern Emirates, DHA for Dubai, DoH for Abu Dhabi and Al Ain, Sharjah Health Authority for Sharjah).

Pharmacovigilance and cold-chain considerations

Amondys 45 vials are stored refrigerated at 2 to 8 degrees Celsius. The shipment chain runs cold from the US specialty distributor to the UAE dispensing pharmacy. Each shipment carries calibrated temperature monitors and a chain-of-custody log. On arrival at the dispensing facility, the pharmacy in charge confirms the temperature record before release. Pharmacovigilance follow-up under the US accelerated approval framework is structured around quarterly renal monitoring (serum cystatin C, urine protein) and annual cardiac and pulmonary surveillance as part of the standard DMD multidisciplinary care plan. Adverse events identified by the treating team route to Sarepta's safety reporting channel and to the EDE post-market surveillance address.

Common questions about Amondys 45 in the UAE

Is my son's mutation amenable to exon 45 skipping? The genetic laboratory report from his diagnostic workup answers this. Sarepta and the FDA-approved label specify the deletions and duplications that read through after exon 45 is skipped. The neuromuscular specialist and the genetic laboratory confirm amenability before any pathway begins.

What about Elevidys (delandistrogene moxeparvovec)? Elevidys is a one-time gene therapy for DMD in ambulatory and non-ambulatory pediatric patients. It is mechanistically distinct from exon-skipping antisense oligonucleotides and the clinical position depends on age, ambulatory status, anti-AAVrh74 antibody status, and the treating team's judgement. Many DMD families weigh both options. The clinical decision rests with the multidisciplinary care team.

Will Daman, Thiqa, or my private insurer cover this? Each insurer assesses pediatric rare-disease cases case by case. Pre-authorisation is the norm. Thiqa, the government-funded programme for UAE nationals administered by Daman, has the broadest specialty coverage in Abu Dhabi. We do not promise coverage from any insurer.

Is Amondys 45 a controlled substance? No. Amondys 45 is not a DEA scheduled substance.

What families ask when they first call

"How does the case actually start?" The family or the treating pediatric neurologist contacts Reserve Meds through the waitlist form. Within 24 to 48 hours, a coordinator confirms eligibility (the genetic confirmation of exon-45-amenable mutation is the central screening question), sends the documentation kit to the physician, and outlines the EDE submission sequence. The family does not pay anything at this stage.

"What if the genetic report is from years ago?" A historical genetic report that confirms the DMD deletion or duplication boundaries is generally acceptable. The treating neurologist confirms the amenability to exon 45 skipping by mapping the boundaries against the FDA-approved label criteria. A fresh laboratory report is not typically required if the original is internally consistent and from a CAP-accredited or comparable laboratory.

"What happens during the inter-infusion weeks?" The once-weekly infusion is the operational rhythm of Amondys 45 therapy. Between infusions, the family continues the DMD multidisciplinary care plan: corticosteroid backbone, cardiac and pulmonary surveillance, physiotherapy, and the planned schedule of orthopaedic, ophthalmologic, and renal assessments. The infusion is one component of a larger care plan, not a standalone treatment.

"What does the renal monitoring look like in practice?" Serum cystatin C and urine dipstick for protein are checked at baseline before therapy and quarterly thereafter. The cystatin C provides a more accurate eGFR estimate in pediatric DMD than creatinine-based formulas because dystrophin-deficient muscle gives a falsely low creatinine. The treating neurologist or nephrologist interprets the trend.

Where Reserve Meds fits in Amondys 45 cases

Reserve Meds is a US-based concierge coordinator. We do not replace your treating neuromuscular specialist, the EDE, or the dispensing pharmacy. For an Amondys 45 case, our work is the regulatory documentation assembly, the US-side procurement coordination with Sarepta's specialty distributor, the refrigerated logistics, the customs handoff, and a single named coordinator for the family through the multi-month onboarding and the ongoing weekly infusion supply. We hold the cold chain end to end. Reserved for you.

Documentation kit for the treating neuromuscular team

The documentation kit Reserve Meds sends the treating neuromuscular team after a waitlist confirmation contains the EDE clinical-justification letter template tailored to exon-skipping antisense oligonucleotide therapy, the weight-based dose-calculation worksheet at 30 mg/kg weekly, the renal monitoring template (serum cystatin C, urine protein) with the quarterly cadence pre-mapped, the DMD multidisciplinary care plan checklist (cardiac, pulmonary, orthopaedic, endocrine, nutrition, psychology), the family informed consent template covering the lifelong infusion commitment and the accelerated approval context, the infusion suite intake checklist, the cold-chain receipt log, and the post-infusion adverse-event capture sheet. The kit is built so the neuromuscular team focuses on the family conversation and the clinical assessment that anchor the EDE submission.

Next step

If a treating pediatric neurologist in the UAE has confirmed an exon-45-amenable DMD mutation and is weighing Amondys 45, the waitlist is the first step. We respond within 24 to 48 hours with an eligibility confirmation and a documentation kit for the physician.

Join the Amondys 45 waitlist

Reserved for you.

Related

• Amondys 45 clinical resource
• Duchenne muscular dystrophy
• United Arab Emirates country page
• Named-patient pathway overview

Sources

1. FDA approval, Amondys 45 (casimersen), Sarepta Therapeutics, accelerated approval February 2021 for DMD amenable to exon 45 skipping.
2. UAE Federal Decree-Law No. 38 of 2024 and the Emirates Drug Establishment portal at ede.gov.ae.
3. Sarepta Therapeutics US prescribing information for Amondys 45 (casimersen), 30 mg/